PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy
Evaluation of the efficacy and safety of Jinyouli in preventing neutropenia in multiple chemotherapy cycles in elderly patients with small cell lung cancer through a multicenter, open, one-arm study Subjects with newly diagnosed small cell lung cancer who met the inclusion/exclusion criteria, chemotherapy regimen: etoposide: 100 mg/m2, d1-3, carboplatin: AUC=5, d1, q21d, prophylactic use test 48 h after chemotherapy Drug PEG-rhG-CSF.
Small Cell Lung Cancer|PEG-rhG-CSF
DRUG: PEG-rhG-CSF
The incidence of grade III/IV neutropenia in the first cycle of PEG-rhG-CSF., The incidence of grade III/IV neutropenia in the first cycle of PEG-rhG-CSF., through first cycle of PEG-rhG-CSF,an average of 1 month|The incidence of grade III/IV neutropenia in the second cycle of PEG-rhG-CSF., The incidence of grade III/IV neutropenia in the second cycle of PEG-rhG-CSF., through second cycle of PEG-rhG-CSF,an average of 1 month
The incidence of febrile neutropenia in cycles 1 and 2, Febrile neutropenia (FN) is defined as oral temperature \>38.3 ° C (underarm temperature \>38.1 ° C) or continuous measurement of oral temperature \>38 ° C (underarm temperature \>37.8 ° C) in 2 h, and ANC \<0.5×10\^9/L, or expected to be \<0.5×10\^9/L, through 1-2 cycles of PEG-rhG-CSF,an average of 2 month|The ANC recovery time in cycles 1 and 2, Defined as the patients who appear ANC\<2.0×10\^9/L，from the first day of chemotherapy, to the time of ANC≥ 2.0×10\^9/L, take the median., through 1-2 cycles of PEG-rhG-CSF,an average of 2 month|The incidence of infection, up to 30 days after the patient study completion|The incidence of antibiotic use, up to 30 days after the patient study completion|Incidence of chemotherapy dose adjustment due to neutropenia, through the study completion,an average of 3 months|Chemotherapy delay time, through the study completion,an average of 3 months|Incidence of chemotherapy delay caused by neutropenia, through the study completion,an average of 3 months|The duration of febrile neutropenia in cycles 1 and 2, through 1-2 cycles of PEG-rhG-CSF,an average of 2 month
Incidence and severity of adverse events, All adverse events will be recorded from the time of signing the informed consent form to 30 days after the last dose. Adverse events 30 days after the last dose, only those adverse events associated with the study drug were recorded., through the study completion,an average of 3 months
Evaluation of the efficacy and safety of Jinyouli in preventing neutropenia in multiple chemotherapy cycles in elderly patients with small cell lung cancer through a multicenter, open, one-arm study Subjects with newly diagnosed small cell lung cancer who met the inclusion/exclusion criteria, chemotherapy regimen: etoposide: 100 mg/m2, d1-3, carboplatin: AUC=5, d1, q21d, prophylactic use test 48 h after chemotherapy Drug PEG-rhG-CSF.